Results 11 to 20 of about 1,025,722 (378)

Schizophrenia [PDF]

open access: yesThe Lancet, 2016
Schizophrenia is a complex, heterogeneous behavioural and cognitive syndrome that seems to originate from disruption of brain development caused by genetic or environmental factors, or both. Dysfunction of dopaminergic neurotransmission contributes to the genesis of psychotic symptoms, but evidence also points to a widespread and variable involvement ...
A. Vita   +4 more
semanticscholar   +9 more sources

Schizophrenia [PDF]

open access: yesThe Lancet, 2022
Schizophrenia, characterised by psychotic symptoms and in many cases social and occupational decline, remains an aetiological and therapeutic challenge. Contrary to popular belief, the disorder is modestly more common in men than in women. Nor is the outcome uniformly poor.
Jauhar, Sameer   +2 more
openaire   +3 more sources

Schizophrenia [PDF]

open access: yesMedicine, 2012
Schizophrenia is a severe mental illness affecting several domains of cognition and behaviour. The illness most frequently becomes manifest in early adulthood, and often follows a chronic course. It is associated with high morbidity and mortality, and is a leading contributor to disease burden, health and social care costs throughout the world ...
Meyer, Nicholas, MacCabe, James H.
openaire   +7 more sources

Motor deficits in schizophrenia quantified by nonlinear analysis of postural sway. [PDF]

open access: yes, 2012
Motor dysfunction is a consistently reported but understudied aspect of schizophrenia. Postural sway area was examined in individuals with schizophrenia under four conditions with different amounts of visual and proprioceptive feedback: eyes open or ...
Bolbecker, Amanda R.   +6 more
core   +10 more sources

Mortality in people with schizophrenia: a systematic review and meta‐analysis of relative risk and aggravating or attenuating factors

open access: yesWorld Psychiatry, 2022
People with schizophrenia die 15‐20 years prematurely. Understanding mortality risk and aggravating/attenuating factors is essential to reduce this gap.
C. Correll   +10 more
semanticscholar   +1 more source

Schizophrenia

open access: yesDeutsches Ärzteblatt international, 2020
The lifetime prevalence of schizophrenia is 1%. Schizophrenia is among the most severe mental illnesses and gives rise to the highest treatment costs per patient of any disease. It is characterized by frequent relapses, marked impairment of quality of life, and reduced social and work participation.The group entrusted with the creation of the German ...
Hasan, Alkomiet   +3 more
openaire   +6 more sources

Bullying among children and adolescents in the SAARC countries: A scoping review

open access: yesHeliyon, 2022
Background: Bullying is defined as repetitive and intentional aggression by an individual or group towards other individuals that happens in a power differential between the individuals being bullied and the bullies.
Shiva Prakash Srinivasan   +4 more
doaj   +1 more source

Learnings from conducting mental health research during 2004 tsunami in Tamil Nadu, India

open access: yesBMC Public Health, 2020
Background The Indian Ocean tsunami experience in 2004 caused a major loss of life and subsequent emotional trauma for survivors. Psychosocial needs in the aftermath of this disaster were extensive, yet the cohesion and effectiveness of response were ...
R. Padmavati   +6 more
doaj   +1 more source

Reductions in midbrain GABAergic and dopamine neuron markers are linked in schizophrenia

open access: yesMolecular Brain, 2021
Reductions in the GABAergic neurotransmitter system exist across multiple brain regions in schizophrenia and encompass both pre- and postsynaptic components.
Tertia D. Purves-Tyson   +4 more
doaj   +1 more source

Cognitive and negative symptoms in schizophrenia with L‐Carnosine adjuvant therapy – A randomized double‐blind placebo‐controlled study

open access: yesPharmacology Research & Perspectives, 2023
The antioxidant L‐Carnosine is reported to improve negative and cognitive symptoms in Schizophrenia. A randomized double‐blind placebo‐controlled study was planned to study the effectiveness of adjuvant L‐Carnosine therapy in patients with Schizophrenia.
Hema Tharoor   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy